

Mometasone Ointment Formulation

Version 2.1 Revision Date: 10.10.2020 SDS Number: 1758837-00008 Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mometasone Ointment Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION**Manufacture, Storage and Import of Hazardous Chemicals Rules 1989****Classification**

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Serious eye damage/eye irritation : Category 2A

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H319 Causes serious eye irritation.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear eye protection/ face protection.

Response:

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337 + P317 If eye irritation persists: Get medical help.

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	>= 70 - < 90
2-Methyl-2,4-pentanediol	107-41-5	>= 10 - < 20
Propylene glycol monostearate	1323-39-3	>= 1 - < 5
Mometasone	83919-23-7	>= 0.1 - < 0.25

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes serious eye irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
-

Mometasone Ointment Formulation

Version 2.1 Revision Date: 10.10.2020 SDS Number: 1758837-00008 Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m ³	IN OEL
		STEL (Mist)	10 mg/m ³	IN OEL
2-Methyl-2,4-pentanediol	107-41-5	TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
		TWA (Vapour)	25 ppm	ACGIH
		STEL (Vapour)	50 ppm	ACGIH
Propylene glycol monostearate	1323-39-3	STEL (Inhalable fraction, Aerosol only)	10 mg/m ³	ACGIH
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
Mometasone	83919-23-7	TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
		TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

- Engineering measures** : Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Combined particulates and organic vapour type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : ointment
- Colour : white to off-white
- Odour : No data available
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : > 93.3 °C
- Evaporation rate : No data available

SAFETY DATA SHEET



Mometasone Ointment Formulation



Version 2.1 Revision Date: 10.10.2020 SDS Number: 1758837-00008 Date of last issue: 23.03.2020
Date of first issue: 14.06.2017

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : Not applicable

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Vapours may form explosive mixture with air.
Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Skin contact

Mometasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 23.03.2020
2.1 10.10.2020 1758837-00008 Date of first issue: 14.06.2017

Skin corrosion/irritation

Not classified based on available information.

Components:**Petrolatum:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

2-Methyl-2,4-pentanediol:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Propylene glycol monostearate:

Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Petrolatum:**

Species : Rabbit
Method : OECD Test Guideline 405
Result : No eye irritation
Remarks : Based on data from similar materials

2-Methyl-2,4-pentanediol:

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days

Mometasone:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Components:**Petrolatum:**

Test Type	:	Buehler Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

2-Methyl-2,4-pentanediol:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative

Mometasone:

Test Type	:	Maximisation Test
Exposure routes	:	Dermal
Species	:	Guinea pig
Assessment	:	Does not cause skin sensitisation.
Result	:	negative
Remarks	:	The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

Components:**Petrolatum:**

Genotoxicity in vitro	:	Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials
-----------------------	---	---

Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials
----------------------	---	--

2-Methyl-2,4-pentanediol:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative
		Test Type: Chromosome aberration test in vitro

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Petrolatum:**

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years
Dose : 0.067 mg/kg body weight
Result : negative

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Species	:	Mouse
Application Route	:	Inhalation
Exposure time	:	19 Months
Dose	:	0.160 mg/kg body weight
Result	:	negative

Reproductive toxicity

Not classified based on available information.

Components:**Petrolatum:**

Effects on fertility	:	Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials
----------------------	---	--

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Skin contact Result: negative Remarks: Based on data from similar materials
-------------------------------	---	--

2-Methyl-2,4-pentanediol:

Effects on fertility	:	Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 421 Result: negative
----------------------	---	--

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: negative
-------------------------------	---	---

Mometasone:

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
----------------------	---	---

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-
-------------------------------	---	--

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

tal toxicity

Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight
 Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Dermal
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Subcutaneous
 Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight
 Result: Effects on newborn

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight
 Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:**Mometasone:**

Exposure routes : inhalation (dust/mist/fume)
 Target Organs : Immune system, Liver, Kidney, Skin
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Petrolatum:**

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Species : Rat
 NOAEL : 5,000 mg/kg
 Application Route : Ingestion
 Exposure time : 2 yr

2-Methyl-2,4-pentanediol:

Species : Rat
 NOAEL : >= 450 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Method : OECD Test Guideline 408

Mometasone:

Species : Rat
 NOAEL : 0.005 mg/kg
 LOAEL : 0.3 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
 LOAEL : 0.5 mg/kg
 Application Route : Oral
 Exposure time : 30 d
 Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
 NOAEL : 0.00013 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 90 d
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species : Dog
 NOAEL : 0.0005 mg/l
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 90 d
 Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Experience with human exposure**Components:****2-Methyl-2,4-pentanediol:**

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Eye contact : Target Organs: Eyes
Symptoms: Irritation

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information**Components:****Mometasone:**

Remarks : Dermal absorption possible

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Petrolatum:**

Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 10 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Toxicity to fish : LC50 (Gambusia affinis (Mosquito fish)): 8,510 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 2,800 mg/l
Exposure time: 48 h

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC10 (Pseudokirchneriella subcapitata (green algae)): > 429 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC: 200 mg/l
Exposure time: 10 d

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC: 0.00014 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.34 mg/l
 Exposure time: 21 d
 Species: Daphnia magna (Water flea)
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 100

Persistence and degradability**Components:****Petrolatum:**

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 31 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301F
 Remarks: Based on data from similar materials

2-Methyl-2,4-pentanediol:

Biodegradability : Result: Readily biodegradable.
 Biodegradation: 81 %
 Exposure time: 28 d
 Method: OECD Test Guideline 301F

Mometasone:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 50 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 % (12 d)
 Method: OECD Test Guideline 111

Bioaccumulative potential**Components:****2-Methyl-2,4-pentanediol:**

Partition coefficient: n-octanol/water : log Pow: 0
 Remarks: Calculation

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
 Bioconcentration factor (BCF): 107.1
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

Mobility in soil**Components:****Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Mometasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Mometasone)
Class : 9
Packing group : III
Labels : 9

Mometasone Ointment Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture****The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

IN OEL : India. Permissible levels of certain chemical substances in work environment.

ACGIH / TWA : 8-hour, time-weighted average

ACGIH / STEL : Short-term exposure limit

IN OEL / TWA : Time-Weighted Average Concentration (TWA) (8 hrs.)

IN OEL / STEL : Short-term exposure Limit STEL (15 min)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

SAFETY DATA SHEET



Mometasone Ointment Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.1	10.10.2020	1758837-00008	Date of first issue: 14.06.2017

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN